XXXX in combination with 1-day versus 3-day @entity619 for prevention of @entity1209 following @entity1311 and @entity3003 in @entity1 with @entity5 : A randomized, multicenter, phase-II trial.

@entity1 @entity43 @entity9170 @entity5 @entity3003 @entity7494 @entity1311 @entity619 @entity11535 @entity7274 @entity1209
AIM: @entity1209 ( @entity1209 ) can affect a @entity1 's quality of life, leading to poor compliance with further treatments. Previous studies have provided minimal data about @entity3003 -based regimens. Female sex is a known risk factor for @entity1209 . The purpose of this study was to evaluate @entity7274 plus single-dose @entity619 ( @entity9170 ) for preventing @entity1209 caused by @entity3003 plus @entity1311 combination therapy (TC regimen) in @entity1 with @entity5 . MATERIAL AND METHODS: @entity1 were recruited for this phase-II, multicenter, randomized trial from 12 hospitals in Hokkaido, Japan. Eligible @entity1 were @entity1 with uterine cervical, @entity43 scheduled to receive conventional TC regimen or dose-dense TC regimen; 116 @entity1 were randomly assigned to receive @entity7274 in combination with 1-day @entity9170 or 3-day @entity9170 . RESULTS: During the overall period, complete response (CR) was observed in 67.9% (95% confidence interval, 53.7-80.1) of @entity1 in the 3-day @entity9170 arm, and 60.7% (95% confidence interval, 46.8-73.5) of @entity1 in the 1-day @entity9170 arm; CR was significantly lower in the 1-day @entity9170 arm if @entity11535 was already present (P   =   0.0370). In the severe @entity7494 gravidarum cohort, CR in the 1-day @entity9170 arm tended to be lower than in the 3-day @entity9170 arm. CONCLUSION: Combination therapy of @entity7274 and 1-day @entity9170 was effective for subjects undergoing a TC regimen for @entity5 . However, the possibility of reduced efficacy of 1-day only @entity9170 therapy in @entity1 undergoing a TC regimen could not be refuted and requires further investigation.
